Article Figures & Data
Figures
- Figure 1.
ACR Responses by Dose at 12 Weeks.
Reproduced with permission from E. Keystone, MD. Keystone et al. Ann Rheum Dis 2012;71[Suppl3].
Tools
12-Week Results of a Phase 2b Dose-Ranging Study of Baricitinib (LY3009104) in Combination with Traditional DMARDs in Patients with RA
Permalink:
Table of contents
Cited By...
- No citing articles found.